Oral human

In one study by Hood et al., 282 of 1153 identified proteins were identified by at least 2 unique tryptic peptides from FFPE prostate cancer (PCa) tissue.9 According to the gene ontology classification of the proteins identified, -65% of proteins were predicted to be intracellular proteins, while -50% of the total human proteome is predicted to be located in the intracellular compartment. Additionally, 20% of the proteins identified in the PCa tissue were classified as membrane proteins, which is significantly less than the predicted 40% for the human proteome. This relative disparity is not unexpected, considering the Liquid Tissue sample preparation kit lacks specific protocols for membrane protein extraction. The Liquid Tissue method has also been used for proteomics studies of a variety of FFPE tissue samples, including pancreatic tumors,28 squamous cell carcinoma,4 and oral human papillomavirus lesions.27... 

Subject N Applica- Monkeys 3 i.v. Humans 12 Oral Humans 6 OraP Humans 13 Oral Humans 13 Oral ... 

Causes conjunctivitis, corneal opacities, irritation of skin and blistering, nausea, vomiting, jaundice, anemia, diarrhea, cyanosis, liver toxicity, and methemoglobinemia.4,5 Animal carcinogen. Reasonably anticipated to be a human carcinogen. LD50 (oral, human) 50 mg/kg LD50 (oral, rat) 500 mg/kg.3... 

The safety, immunogenicity, and efficacy of a live oral human rotavirus vaccine 89-12 has been assessed in 213 US infants in a randomized, placebo-controUed, doubleblind, multicenter trial (2). The infants received two doses of vaccine or placebo and were followed up through one rotavirus season. There was an immune response to vaccine in 94.4% of vaccinees, and vaccine efficacy was 89%. Adverse reactions were mild. Low-grade fever after the first dose was the only adverse effect that was significantly more common with the vaccine than with placebo. 

Most adverse effects reported relate to the therapeutic use of cetrimide. If ingested orally, cetrimide and other quaternary ammonium compounds can cause nausea, vomiting, muscle paralysis, CNS depression, and hypotension concentrated solutions may cause esophageal damage and necrosis. The fatal oral human dose is estimated to be 1.0-3.0g. ... 

The probable lethal oral human dose is greater than 15 g/kg. 

Oral human LDlq is equal to 221 mgkg Adverse acute reactions to bismuth include acute renal failure following ingestion of excessive concentrations. Bismuth can cause nausea, vomiting, and abdominal pain within hours of exposure. Muscle cramps and weakness, blurred vision, and hyperreflexia may be exhibited. Liver transaminase activities may be elevated. 

Mena etal. 1969-oral human study Mena etal. 1967 Mena etal. 1967 Mena etal. 1967... 

Bromine is an active corrosive poison, which is almost instantaneously injurious to the skin. Its vapor is very irritating to the mucous membranes of the eyes, nose, throat, and lungs, but its odor gives good warning. Direct contact of the liquid with the skin destroys tissues and causes painful burn that heals slowly. Lethal intake of bromine LD50 (Br2, oral, human) is ca. 1 g. 

HUMAN HEALTH RISKS Oral human LD50 3 mg/kg Acute Risks headache weakness excessive salivation abdominal cramps vomiting difficulty breathing confusion ataxia wheezing cardiac irregularity sweating rhinorrhea cyanosis vision problems paralysis respiratory failure spasms coma death Chronic Risks depressed red blood cell cholinesterase activity liver effects headaches depressed plasma birth defects. 

HUMAN HEALTH RISKS Oral human LDLo 14 mg/kg Acute Risks irritation of skin, eyes and mucous membranes weakness spasms weak pulse reduced blood pressure loss... 

HUMAN HEALTH RISKS Oral human TDLo 30 mg/kg inhalation human TCLo 1000 mg/m for 30 minutes Acute Risks irritation of eyes, mucous membranes and upper respiratory tract burning sensation coughing dermatitis CNS depression gastrointestinal effects death Chronic Risks blood effects heart damage possible human carcinogen jaundice CNS effects may alter genetic material. 

HUMAN HEALTH RISKS Oral human LDL 50 mg/kg eye human 300 ppm inhalation human TCLo 200 ppm Acute Risks irritation of eyes, skin and upper respiratory tract burning sensation headache shortness of breath nausea chest pain edema death Chronic Risks dermatitis anemia decreased blood cell count bone marrow hypoplasia CNS effects. 

HUMAN HEALTH RISKS Oral human LDLo 28 mg/kg skin human TDLo 657 mg/kg EPA Group B2 probable human carcinogen Acute Risks irritation of skin diarrhea CNS stimulation allergic skin dermatitis vomiting respiratory failure somnolence intermittent convulsions seizures coma death Chronic Risks reversible respiratory toxicity weight loss loss of appetite reversible deafhess and disorientation. 

HUMAN TOXICITY DATA oral-human TDLo 1470 mg/kg in-halation-human TCLo 816ppm/3M skin-human 50 mg/24H. 

HUMAN TOXICITY DATA oral-human TDLq 570 mg/kg inhalation-human TCLq 160ppm/4H. 

HUMAN TOXICITY DATA oral-human TDLO I4mg/kg cyt-human lym 1900mg/L cyt-human leu 19,125 g/L. 

HUMAN TOXICITY DATA oral-human TDLo 130 mg/kg toxic effect central nervous system inhalation - human LCLo 20,000 ppm/5 months inhalation-human TCLo 210 ppm toxic effect blood inhalation-human TCLo 100 ppm/10 years - intermittent toxic effect carcinogenic EPA Cancer Risk Level (1 in a million excess lifetime risk) 1.0 x 10 mg/m. ... 

HUMAN TOXICITY DATA oral-human LDLo 14mg/kg inhalation-human LCLo lOOOppm. 

HUMAN TOXICITY DATA oral-human LDLo 143 mg/kg sce-human lymphocyte 80p.mol/L EPA Cancer Risk Level (1 in a million excess lifetime risk) 9x10 mg/m. ... 

HUMAN TOXICITY DATA oral-human LDLo 29mg/kg toxic effect liver skin-human LDLo 428mg/kg toxic effect central nervous system sce-human lymphocyte lOpmol/L oral-man TDLo 3071pg/kg unreported-man LDLo 118mg/kg oral-woman LDLo 120pg/kg toxic effects central nervous system, gastrointestinal tract. 

HUMAN TOXICITY DATA sce-human lymphocyte 10 imol/L oral-human LDLo... 

HUMAN TOXICITY DATA inhalation-human LCLo 25,000ppm/5months inhalation-human TCLo 5000mg/m /7months oral-human LDLo 140mg/kg.. 

---